OGEN .625 Drug Patent Profile
✉ Email this page to a colleague
When do Ogen .625 patents expire, and when can generic versions of Ogen .625 launch?
Ogen .625 is a drug marketed by Pfizer and is included in one NDA.
The generic ingredient in OGEN .625 is estropipate. There are two drug master file entries for this compound. Additional details are available on the estropipate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OGEN .625?
- What are the global sales for OGEN .625?
- What is Average Wholesale Price for OGEN .625?
Summary for OGEN .625
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 62 |
Patent Applications: | 2,766 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OGEN .625 at DailyMed |
US Patents and Regulatory Information for OGEN .625
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pfizer | OGEN .625 | estropipate | TABLET;ORAL | 083220-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |